Gene · 7507
XPA: XPA, DNA damage recognition and repair factor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. XPA: XPA, DNA damage recognition and repair factor. Genes, record 7507. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7507
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P23025 | DNA repair protein complementing XP-A cells | 273 | 18 | Ensembl, GeneID, HGNC |
Source UniProt
Patents49
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 9581 | P23025 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9833 | P23025 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9833 | P23025 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 9581 | P23025 | Espacenet |
| EP 4524569 A2 | 2025-03-19 | 28 | P23025 | Espacenet |
| EP 4464338 A2 | 2024-11-20 | 375 | P23025 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 9103 | P23025 | Espacenet |
| US 12023339 B2 | 2024-07-02 | 28 | P23025 | Espacenet |
| US 11976334 B2 | 2024-05-07 | 217 | P23025 | Espacenet |
| US 11680268 B2 | 2023-06-20 | 375 | P23025 | Espacenet |
1 to 10 of 49
See all 49 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,816
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | XPA papers | Newest fiscal year |
|---|---|---|---|
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 43 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 26 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 24 | 2025 |
| R01CA093729 | Repair of Genome Destabilizing DNA Structures | 19 | 2025 |
| R35GM118102 | Molecular Mechanism of Mammalian DNA Excision Repair and the Circadian Clock | 12 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 11 | 2025 |
| P30CA177558 | University of Kentucky Markey Cancer Center – Cancer Center Support Grant | 11 | 2025 |
| P30CA047904 | Cancer Center Support Grant | 10 | 2025 |
| P30CA118100 | University of New Mexico Cancer Center Support Grant | 10 | 2025 |
| P30CA014599 | Cancer Center Support Grant | 9 | 2025 |
1 to 10 of 1,816Source NIH's project files
See all 1,816 nih grantsPapers3,297
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Correction to: An XPA gene splicing mutation resulting in trace protein expression in an elderly patient with xeroderma pigmentosum group A without neurological abnormalities. | Br J Dermatol | 2026 | 42715004 | PubTator, text mining | PubMed |
| XPA confers ability of endonucleases to act processively and to incise damaged nucleosomal DNA. | Exp Biol Med (Maywood) | 2026 | 42643815 | PubTator, text mining | PubMed |
| Host DNA repair factors empower a mechanism of antiviral nucleoside analog resistance. | Proc Natl Acad Sci U S A | 2026 | 42607204 | PubTator, text mining | PubMed |
| AAV-mediated gene therapy demonstrates phenotypic rescue in a mouse model of Cockayne syndrome. | J Clin Invest | 2026 | 42531030 | PubTator, text mining | PubMed |
| Whole-exome sequencing reveals novel and previously reported variants in genes linked to white matter pathology in neurodevelopmental disorders. | Eur J Hum Genet | 2026 | 42420565 | PubTator, text mining | PubMed |
| Recruitment and release of XPG during NER is controlled by pre- and post-incision factors and EXO1. | J Cell Biol | 2026 | 42377264 | PubTator, text mining | PubMed |
| Vitamin D Supplementation Modulates Base Excision Repair (BER) Machinery in Systemic Sclerosis: A Prospective Longitudinal Study. | Biochem Genet | 2026 | 42258083 | PubTator, text mining | PubMed |
| XPC and global genome nucleotide excision repair are essential for telomere stability after UVC-induced DNA damage in human cells. | DNA Repair (Amst) | 2026 | 42247759 | PubTator, text mining | PubMed |
| Host DNA repair factors empower a mechanism of antiviral nucleoside analog resistance. | bioRxiv | 2026 | 42239149 | PubTator, text mining | PubMed |
| Engineering quantum dot surfaces to preserve protein-DNA interactions for single-molecule visualization. | Nano Converg | 2026 | 42234051 | PubTator, text mining | PubMed |
1 to 10 of 3,297
See all 3,297 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7507
GET https://conductscience.org/api/genes/v1/7507/patents?page=2